Could personalized medicine be the driver for widespread price controls?

Yali Friedman
Journal of Commercial Biotechnology

DOI:https://doi.org/10.5912/jcb559

Abstract:

Everyone should agree that the benefits of personalized medicine — prescription of drugs most likely to benefit and least likely to harm individual or groups of patients — are are positive. However, one must consider the potential practical challenges of increased implementation of personalized medicine, if the current healthcare delivery system is compatible with personalized medicine, and what regulatory/policy changes may be needed to accomodate personalized medicine.

Keywords:personalized medicine ,comparative effectiveness ,orphan drugs ,economics ,pricing ,en ,